Royalty Pharma (STU:RPD) EPS (Basic): €1.64 (TTM As of Mar. 2026)


STU:RPD Royalty Pharma PLC STU:RPD
72 GF Score
Price €48.03
GF Value €32.95
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma EPS (Basic)?

Royalty Pharma STU:RPD +0.52% 72 EPS (Basic) is €1.64 as of Mar. 2026. GuruFocus rates STU:RPD with a GF Score™ of 72/100 and a GF Value™ of €32.95 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Royalty Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €0.58. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.64.

Royalty Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was €0.58. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.54.

Royalty Pharma's EPS without NRI for the three months ended in Mar. 2026 was €0.73. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1.58.

During the past 12 months, Royalty Pharma's average EPS without NRIGrowth Rate was -20.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 8.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Royalty Pharma's highest 3-Year average EPS without NRI Growth Rate was 30.70% per year. The lowest was -39.80% per year. And the median was -8.20% per year.

Royalty Pharma  (STU:RPD) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Royalty Pharma EPS (Basic) Related Terms

Royalty Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma EPS (Basic) Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only 1.32 0.09 2.33 1.83 1.53

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.06 0.57 0.43 0.58
STU:RPD
72GF Score
Royalty Pharma PLC STU:RPD
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Royalty Pharma's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(658.389-0)/429.801
=1.53

Royalty Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(254.907-0)/436.790
=0.58

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €1.64 mean?
Royalty Pharma (STU:RPD) has a EPS (Basic) of €1.64 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's EPS (Basic) too high?
Royalty Pharma's current EPS (Basic) is €1.64. Overall, Royalty Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's EPS (Basic) compare to BNTX and INSM?
Royalty Pharma's EPS (Basic) of €1.64 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current EPS (Basic) is €1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (STU:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.95, compared to a current price of €48.03 — trading 45.8% above its estimated fair value. The current EPS (Basic) is €1.64. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Royalty Pharma (STU:RPD), the current EPS (Basic) is €1.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (STU:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €48.03 is trading 45.8% above its estimated GF Value™ of €32.95. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for STU:RPD:

  • EPS (Basic): €1.64
  • GF Value™: €32.95 vs. price of €48.03 (45.8% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the STU:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for STU:RPD

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.03
Price
€32.95
GF Value